Key Takeaways EMA granted ODD to efdoralprin alfa after the phase II ElevAATe study met endpoints.The study showed Q3W and Q4W dosing significantly improved outcomes versus weekly plasma-derived therapy.SNY added efdoralprin alfa via the Inhibrx acquisition and the drug already holds FDA Fast Track and ODD.Sanofi (SNY) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (“ODD”) to efdoralprin alfa (SAR447537, formerly known as INBRX-101), an investigational biologic drug f ...